Why the study?
Does simultaneous 18F-FDG PET/MRI improve the detection of myocardial involvement and reduce radiation dose compared to PET/CT and cardiac MRI in patients with suspected cardiac sarcoidosis or myocarditis?
Does simultaneous 18F-FDG PET/MRI improve the detection of myocardial involvement and reduce radiation dose compared to PET/CT and cardiac MRI in patients with suspected cardiac sarcoidosis or myocarditis?
Simultaneous 18F-FDG PET/MRI is feasible for evaluating cardiac sarcoidosis and myocarditis, offering potentially higher detection rates with significantly lower radiation doses compared to PET/CT.
May support higher detection of cardiac involvement with lower radiation in sarcoidosis or myocarditis; hypothesis-generating and requires larger prospective validation.
PURPOSE: The purpose of this study was to compare combined PET/MRI with PET/CT and cardiac MRI in the evaluation of cardiac sarcoidosis and myocarditis. METHODS: Ten patients (4 men and 6 women; 56.1 ± 9.6 years old) were prospectively enrolled for evaluation of suspected cardiac sarcoidosis or myocarditis. Written informed consent was obtained. Following administration of 9.9 ± 0.9 mCi F-FDG, patients underwent standard cardiac PET/CT followed by combined PET/MRI using a simultaneous 3-T scanner. Cardiac MRI sequences included ECG-triggered cine SSFP, T2-weighted, and late gadolinium-enhanced imaging. Myocardial involvement was assessed with separate analysis of combined PET/MRI, PET/CT, and cardiac MRI data using dedicated postprocessing software. Estimates of radiation dose were derived from the applied doses of F-FDG and CT protocol parameters. RESULTS: Imaging was acquired with a delay from F-FDG injection of 90.2 ± 27.4 minutes for PET/CT and 207.7 ± 40.3 minutes for PET/MRI. Total scan time for PET/MRI was significantly longer than for PET/CT (81.4 ± 14.8 vs 12.0 minutes, P < 0.001). Total effective radiation dose was significantly lower for PET/MRI compared with PET/CT (6.9 ± 0.6 vs 8.2 ± 1.1 mSv, P = 0.007). There was no significant difference in the number of positive cases identified between combined PET/MRI (n = 10 [100%]), PET/CT (n = 6 [60%]), and cardiac MRI (n = 8 [80%]), P = 0.091. CONCLUSIONS: Simultaneous cardiac PET/MRI is feasible in the evaluation of cardiac sarcoidosis and myocarditis achieving diagnostic image quality.
No takes yet. Share an insight, caveat, or question.
Hanneman et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: